Happy Sunday everyone! We're the official account for The Journal of Infectious Diseases – an official journal of @IDSAInfo. Follow us for updates and to comment on the latest articles from JID, the premier global journal for original research on infectious diseases.
Hi everyone! 👋 We're the official account for Clinical Infectious Diseases. An official journal of @IDSAinfo, CID is one of the world's leading journals on ID. Follow us to stay up to date and comment on high-quality articles on clinical ID, public health, microbiology & more.
Hello there! We're the official account for Open Forum Infectious Diseases – an official journal of @IDSAInfo. OFID publishes clinical, translational and basic research in a fully open access, online journal. Follow us to stay up to date and comment on all our latest content.
@RicardoLaHozMD @jfsisaacs5 @matthew_mei @AaronGoodman33 @nihardesai7@ftorriani @DeepaDNanayakk1 Maribavir is a/w less AKI and cytopenia than FOS and VGCV/GCV, respectively. However, it is only FDA approved for R/R CMV. It can only be given PO so if there is no issues with oral intake (conditioning-related GI toxicity or acute GI GVHD) it may be an off-label option
Finally got to analyze & put my thoughts together on the recent #posaconazole vs. #voriconazole phase 3 trial for invasive #aspergillosis published in .@TheLancet a few weeks ago.
Best is to put the major trials of the 3 #VIP triazoles done over the last 20 years in perspective!
New job opportunity @cityofhope - Assistant Clinical Professor in Infectious Diseases w/ a focus on HCT and cancer pts. Great team of experts that you would be joining.
Plus ☀️ California...
See here for more information
https://t.co/s54tXh81hy
Happy to share our research letter on TMP-SMX avoidance and nocardiosis - 💊TMP-SMX allergy evaluation/rechallenge on pts receiving 2nd line PJP ppx may allow its tolerance and could prevent other OIs - Great work @AnneLiuMD@ArunaSubraman12 !! https://t.co/9XCicqhPxC
Today, FDA amended the emergency use authorizations (EUAs) for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals. https://t.co/MYoTvX82lM
@RazonableMD Thank you @RazonableMD. Happy to share our experience @cityofhope showing that mAb therapy against COVID-19 is safe and effective in cancer patients who are at high risk for disease progression and mortality.
FDA authorizes REGEN-COV (casirivimab-imdevimab) for post-exposure prophylaxis in adults and pediatric individuals who are at high risk for progression to severe COVID-19, including hospitalization or death. https://t.co/X6YTd9Wmbq
Una poesía con versos aclamados por un pequeño pueblo. Este oro es para quien realmente ha creído en mí. También para mis hijos, esposa y mis padres. Los amo! Sepan seguro que los días más grandes se escriben con la misma tinta de olimpo. Gracias Ecuador 🇪🇨
In California, the Delta variant is 30% of cases, and vaccinations are fairly high (>61% population 1-dose or more), cases have started to creep up again, 17% in past 2 weeks and that's with 62% less testing (<-complacency)
Next #IDJClub: May 3 (9pm EDT)
In honor of our late colleague and friend Francisco Marty, a giant in the field of infections of immunocompromised hosts, we’ll discuss posaconazole vs voriconazole as primary therapy for invasive #aspergillosis
https://t.co/g3YFmwcXKF